Acquired <i>EGFR</i> Resistance Mutation C797S in Pancreatic Adenocarcinoma Following Partial Response to Third-Generation EGFR Inhibitor Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Acquired EGFR Resistance Mutation C797S in Pancreatic Adenocarcinoma Following Partial Response to Third-Generation EGFR Inhibitor Therapy

Published:2024-07 Issue:8 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precis Oncol

Author:

Papa Brigitte¹,Dorwal Pranav¹²³^ORCID,Htain Pamela²,Robin Julie²,Tan C.P.⁴,Singhal Nimit⁴

Affiliation:

1. Department of Anatomical Pathology, Monash Health, Melbourne, Australia

2. Diagnostic Genomics, Monash Health, Melbourne, Australia

3. School of Clinical Sciences, Monash University, Melbourne, Australia

4. Cancer Centre, Royal Adelaide Hospital and School of Medicine, University of Adelaide, South Australia, Australia

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.24.00132

Reference19 articles.

1. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

2. Targeted Therapies for Pancreatic Cancer

3. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

4. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

5. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP